Zoetis Inc.

ZTS | NYSE

Price Alert Chart Builder DCF Calculator

$82.11

-$7.09 (-7.95%)

At close: Nov 5, 2026, 4:00 PM ET

$82.29

+$0.18 (+0.22%)

After-hours: Nov 5, 2026, 5:56 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

-7.95%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

66.2

Fundamentals Strong

Market Sentiment Bullish

Moat Wide

Sector Rank #82/1024 (Top 8%)

Full Analysis

Key Statistics

Market Data

Market Cap $33.93B

1D Range

81.54 88.74

52W Range

69.10 131.10

Valuation (TTM)

PE 14.69

PB 11.70

EV/EBITDA 11.46

Valuation (NTM)

Forward PE 14.06

Forward PEG -6.85

Price Target $84.75

Cash Flow

FCF Yield 6.4%

SBC Adj. FCF Yield 6.2%

SBC Impact -4.0%

Margins

Gross Margin 70.9%

Operating Margin 37.0%

FCF Margin 24.9%

Growth (CAGR)

Revenue 3Y | 5Y 5.0% | 5.1%

Dil EPS 3Y | 5Y 8.4% | 8.8%

FCF 3Y | 5Y 22.6% | 6.8%

Returns

ROA 17.4%

ROE 69.3%

ROIC 21.6%

Financial Health

Net Debt

$7.37B

Current Ratio 3.08

Interest Coverage 14.43

Dividends

Div Yield 2.38%

Payout Ratio 34.9%

FCF Payout Ratio 37.6%

All Key Statistics

Loading financial charts...

Profile

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its c...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 14,500

IPO Date Feb 1, 2013

Website www.zoetis.com

Fiscal Year January - December

Full Company Profile

Latest News

8 hours ago · zacks.com

ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up

Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.

9 hours ago · reuters.com

Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall

9 hours ago · benzinga.com

Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy

Zoetis Inc. (NYSE:ZTS) reported third-quarter adjusted earnings of $1.75 per share, beating the consensus of $1.51.

12 hours ago · zacks.com

Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

13 hours ago · zacks.com

Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates

Zoetis (ZTS) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.7 per share a year ago.

1 day ago · seekingalpha.com

Zoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued

Zoetis is emerging from a period of underperformance, with market expectations for Q3 and Q4 set notably low. Consensus and management guidance anticipate revenue and EPS declines, but these expectations appear beatable given ZTS's diversified growth levers. Long-term growth drivers include expanding parasite prevention, resilient livestock sales, and a nascent but promising diagnostics business.

2 days ago · zacks.com

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

ZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.

2 days ago · zacks.com

Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Evaluate the expected performance of Zoetis (ZTS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.